Edesa Biotech, Inc. announced on April 4, 2025, the appointment of Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role on the same date to pursue other professional opportunities.
Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. His previous roles include President of Exzell Pharma, Inc., Vice President of Business Development at Biosyent Inc., and various positions at Cipher Pharmaceuticals Inc. He also held research and financial positions at Eli Lilly Canada Inc.
Following the transition, Mr. Lemieux will continue to provide financial advisory services to Edesa. This change in financial leadership is intended to support the company as it advances its pipeline and explores strategic opportunities for its drug candidates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.